Study Findings from University of Manchester Advance Knowledge in Rheumatoid Arthritis (Population Pharmacokinetic Analysis and Simulation of Alternative Dosing Regimens for Biosimilars to Adalimumab and Etanercept in Patients with Rheumatoid...).

A recent study conducted by researchers at the University of Manchester in the United Kingdom explored the potential for altering dosing intervals of biosimilars to adalimumab and etanercept in patients with rheumatoid arthritis (RA). The study aimed to determine if adjusting the dosing intervals could achieve therapeutic drug levels more quickly or similarly to the recommended interval. The researchers recruited RA patients starting the adalimumab and etanercept biosimilars and analyzed their drug levels using population pharmacokinetic analysis. They found that simulations of altered dosing intervals could potentially lead to personalized dosing studies in the future, which could increase efficacy and potentially save costs. [Extracted from the article]